Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918382 | 0.88 | HTR2C (0.56) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL7013898 | 0.86 | L3MBTL1 (0.67) | MRGPRX4HTR2CSLC6A4HTR2BL3MBTL1 | |
| SCHEMBL1331639 | 0.83 | HTR2C (0.58) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL18703359 | 0.83 | MRGPRX4 (0.61) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL6216861 | 0.82 | HTR2C (0.54) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL1332170 | 0.81 | SLC6A4 (0.56) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL30427926 | 0.81 | MRGPRX4 (0.72) | MRGPRX4 | |
| SCHEMBL5730837 | 0.81 | HTR2C (0.60) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL30821972 | 0.81 | SLC6A4 (0.56) | MRGPRX4HTR2CSLC6A4HTR2BRXRA | |
| SCHEMBL4150404 | 0.81 | HTR2C (0.56) | MRGPRX4HTR2CSLC6A4HTR2BRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540323-B2 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-9428504-B2 | 7-hydroxy-spiropipiperidine indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2892898-B1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-17 | — | — | US | disclosed |
| EP-2892894-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | Bristol-Myers Squibb Company (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2892898-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | Bristol-Myers Squibb Company (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20150166538-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| WO-2014022349-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014022343-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1451159-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003010146-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | MRGPRX4 238/4885HTR2C 1494/4885SLC6A4 1611/4885 |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY11, P2RY2 | MRGPRX4 149/4885HTR2C 38/4885SLC6A4 415/4885 |
| US-20150166538-A1 | 7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY2, P2RY11 | MRGPRX4 676/4885HTR2C 40/4885SLC6A4 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.